High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
Paul J. Hengeveld(Erasmus MC), Anton W. Langerak(Erasmus MC), Mark‐David Levin(Albert Schweitzer Ziekenhuis), Lina van der Straten(Erasmus MC), Peter E. Westerweel(Cornell University), Melissa Rijken(Erasmus MC Cancer Institute), Jorn L. J. C. Assmann(Erasmus MC), Arnon P. Kater(Sanford Burnham Prebys Medical Discovery Institute), P. Martijn Kolijn(Erasmus MC), Jeroen Demmers(Erasmus MC), Peter J.M. Valk(Erasmus MC), Wouter Doff(Erasmus MC), Henk Jan Boiten(Erasmus MC), Kirsten J. Gussinklo(Erasmus MC Cancer Institute), Laura M. Faber(Red Cross Hospital), Julie Dubois(Amsterdam University Medical Centers)
Cited by 5
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907